Stay updated on Johnson & Johnson Press Releases
Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FjO9vIeDZ4FsjyceHMn0_qjG4CEs.uncropped.jpg&w=3840&q=75)
Latest updates to the Johnson & Johnson Press Releases page
- CheckyesterdayChange DetectedThe FDA has received its first submission for nipocalimab to treat antibody positive generalized myasthenia gravis, marking a significant advancement in treatment options, while DePuy Synthes has launched a new fixation system for cardiac surgery, enhancing patient care.SummaryDifference100%
- Check8 days agoChange DetectedThe European Commission has approved RYBREVANT® (amivantamab) and BALVERSA® (erdafitinib) for advanced lung and bladder cancers, respectively, highlighting significant advancements in treatment options for patients with specific mutations and conditions.SummaryDifference100%
- Check15 days agoChange DetectedThe website now features 1,984 results and highlights the acquisition of V-Wave, which offers a novel treatment for heart failure, alongside the approval of RYBREVANT® plus LAZCLUZE™ as a first-line chemotherapy-free option for advanced lung cancer, showing significant efficacy compared to osimertinib.SummaryDifference100%
- Check22 days agoChange DetectedRecent updates include the launch of the TriLEAP™ Lower Extremity Anatomic Plating System by DePuy Synthes, a groundbreaking study on nipocalimab for severe fetal anemia, and a labeling amendment for the LINX™ Reflux Management System to include patients with Barrett’s Esophagus, while notable deletions include the approval of new cancer therapies and quarterly financial results from Johnson & Johnson.SummaryDifference100%
- Check29 days agoChange DetectedThe latest updates highlight significant advancements in cancer treatment, including a new combination therapy for NSCLC that improves progression-free survival and a quadruplet therapy study for multiple myeloma that shows a 60% reduction in disease progression risk.SummaryDifference100%
- Check37 days agoChange DetectedThe website now shows an increase to 1,975 results, and Johnson & Johnson has announced their participation in the 2024 Wells Fargo Healthcare Conference on July 29, 2024.SummaryDifference11%
Stay in the know with updates to Johnson & Johnson Press Releases
Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.